IMIQUIMOD (i-mi'qui-mod) Aldara Classifications: keratolytic agent; immune response modifier; Therapeutic: immune response modifier; keratolytic Pregnancy Category: C |
5% cream in 250 mg single use packets
An immune response modifier; exact mechanism of action is unknown. Induces cytokine production, including interferon-alfa, which may interfere with viral replication.
Does not totally eradicate HPV. Despite destruction of HPV warts, latent or subclinical HPV infection can persist, and recurrence of visible warts is common.
Treatment of external genital and perianal warts (Condylomata acuminata), actinic keratosis on the face and scalp of immunocompetent adults, and superficial basal cell carcinoma.
Treatment of common warts.
Occlusive dressing; ocular exposure; excessive sun exposure or sunburn; UV exposure; surgery or drug treatment on affected area; pregnancy (category C); children <12 y.
Hypersensitivity to benzyl alcohol or paraben; HIV infection; lactation
Genital and Perianal Warts Adult/Adolescent (>12 y): Topical Apply a thin layer to the affected areas once daily 3 times/wk just before bedtime. Wash off cream after 610 h (max: 16 wk therapy). Actinic Keratosis Adult: Topical Apply a thin layer to the affected areas once daily 2 times/wk just before sleep for 16 wk. Wash off cream after 8 h. Superficial Basal Cell Carcinoma Adult: Topical Apply a thin layer to the affected areas once daily 5 times/wk just before sleep for 6 wk. Wash off cream after 8 h. |
Patient & Family Education